Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar 21;21(11):3197-205.
doi: 10.3748/wjg.v21.i11.3197.

Hyponatremia in cirrhosis: pathophysiology and management

Savio John  1 , Paul J Thuluvath  1
Affiliations
Review

Hyponatremia in cirrhosis: pathophysiology and management

Savio John et al. World J Gastroenterol. .

Abstract

Hyponatremia is frequently seen in patients with ascites secondary to advanced cirrhosis and portal hypertension. The development of ascites in patients with cirrhosis is multi-factorial. Portal hypertension and the associated systemic vasodilation lead to activation of the sodium-retaining neurohumoral mechanisms which include the renin-angiotensin-aldosterone system, sympathetic nervous system and antidiuretic hormone (ADH). The net effect is the avid retention of sodium and water to compensate for the low effective circulatory volume resulting in the development of ascites. Although not apparent in the early stages of cirrhosis, the progression of cirrhosis and ascites leads to impairment of the kidneys to eliminate solute- free water. This leads to additional compensatory mechanisms including non-osmotic secretion of ADH, also known as arginine vasopressin, further worsening excess water retention and thereby hyponatremia. Hyponatremia is associated with increased morbidity and mortality in patients with cirrhosis, and is an important prognostic marker both before and after liver transplant. The management of hyponatremia in this setting is a challenge as conventional therapy for hyponatremia including fluid restriction and loop diuretics are frequently inefficacious. In this review, we discuss the pathophysiology and various treatment modalities, including selective vasopressin receptor antagonists, for the management of hyponatremia in patients with cirrhosis.

Keywords: Dilutional hyponatremia; Hypervolemic hyponatremia; Hyponatremia in cirrhosis; Vaptans; Vasopressin receptor antagonists.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proposed mechanisms for the development of hyponatremia. SNS: Sympathetic nervous system; RAAS: Renin-angiotensin-aldosterone system; NO: Nitric oxide; RES: Reticuloendothelial system; PG: Prostaglandin; AVP: Arginine vasopressin; ADH: Antidiuretic hormone.
Figure 2
Figure 2
Mechanisms involved in the splanchnic vasodilation in cirrhosis. ADH: Antidiuretic hormone.
Figure 3
Figure 3
Mechanism of action of vaptans. AVP: Arginine vasopressin; AQP2: Aquaporin-2; AQP3: Aquaporin-3; AQP4: Aquaporin-4.
See this image and copyright information in PMC

References

    1. Baran D, Hutchinson TA. The outcome of hyponatremia in a general hospital population. Clin Nephrol. 1984;22:72–76. - PubMed
    1. Ginés P, Berl T, Bernardi M, Bichet DG, Hamon G, Jiménez W, Liard JF, Martin PY, Schrier RW. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology. 1998;28:851–864. - PubMed
    1. Angeli P, Wong F, Watson H, Ginès P. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology. 2006;44:1535–1542. - PubMed
    1. Abelmann WH. Hyperdynamic circulation in cirrhosis: a historical perspective. Hepatology. 1994;20:1356–1358. - PubMed
    1. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology. 1994;20:1359–1363. - PubMed

MeSH terms

Substances